Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]: evaluation consultation
We are listening to your views on this highly specialised technology. Comments close 06 April 2021.
We are listening to your views on this highly specialised technology. Comments close 06 April 2021.
We are listening to your views on this interventional procedures guidance. Comments close 25 March 2021.
We are listening to your views on this interventional procedures guidance. Comments close 25 March 2021.
We are listening to your views on this interventional procedures guidance. Comments close 25 March 2021.
We are listening to your views on this technology appraisal guidance. Comments close 18 March 2021.
We are listening to your views on this technology appraisal guidance. Comments close 25 March 2021.
We are listening to your views on this technology appraisal guidance. Comments close 26 March 2021.
We are listening to your views on this technology appraisal guidance. Comments close 26 March 2021.
In development [GID-HST10010] Expected publication date: TBC
In development [GID-HST10017] Expected publication date: TBC
In development [GID-HST10028] Expected publication date: 13 August 2021
In development [GID-HST10032] Expected publication date: TBC
In development [GID-HST10033] Expected publication date: TBC
In development [GID-HST10035] Expected publication date: TBC
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
In development [GID-HST10009] Expected publication date: TBC
In development [GID-HST10027] Expected publication date: TBC
In development [GID-HST10043] Expected publication date: 22 January 2022
In development [GID-HST10026] Expected publication date: TBC
In development [GID-NG10050] Expected publication date: TBC
In development [GID-NG10086] Expected publication date: 01 September 2021
In development [GID-NG10140] Expected publication date: 15 December 2021
In development [GID-NG10170] Expected publication date: 16 March 2022
In development [GID-NG10125] Expected publication date: 17 May 2022
In development [GID-NG10142] Expected publication date: 09 February 2022
In development [GID-NG10121] Expected publication date: 27 September 2021
In development [GID-NG10139] Expected publication date: 06 April 2022
In development [GID-IPG10181] Expected publication date: TBC
In development [GID-IPG10179] Expected publication date: TBC
In development [GID-IPG10180] Expected publication date: TBC
In development [GID-IPG10158] Expected publication date: TBC
In development [GID-IPG10159] Expected publication date: TBC
In development [GID-IPG10160] Expected publication date: TBC
In development [GID-IPG10163] Expected publication date: TBC
In development [GID-IPG10165] Expected publication date: TBC
In development [GID-IPG10166] Expected publication date: TBC
In development [GID-IP1180] Expected publication date: TBC
In development [GID-IP1046] Expected publication date: TBC
In development [GID-IPG10205] Expected publication date: TBC
In development [GID-IPG10203] Expected publication date: TBC
In development [GID-IPG10204] Expected publication date: TBC
In development [GID-IPG10147] Expected publication date: 31 March 2021
In development [GID-IPG10164] Expected publication date: 31 March 2021
In development [GID-IPG10184] Expected publication date: TBC
In development [GID-IPG10185] Expected publication date: TBC
In development [GID-IPG10187] Expected publication date: TBC
In development [GID-IPG10151] Expected publication date: 28 April 2021
In development [GID-IPG10143] Expected publication date: 28 April 2021
In development [GID-IPG10191] Expected publication date: TBC
In development [GID-IPG10192] Expected publication date: TBC